You can buy or sell AVEO and other stocks, options, ETFs, and crypto commission-free!
AVEO Pharmaceuticals, Inc. Common Stock, also called AVEO Pharmaceuticals, is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Read More Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 11
AVEO Pharmaceuticals Q1 Earnings & Revenues Miss Mark
AVEO Pharmaceuticals, Inc. AVEO incurred first-quarter 2019 loss of 6 cents per share, wider than the Zacks Consensus Estimate of a loss of 5 cents but narrower than the year-ago loss of 8 cents. AVEO’s top line comprises collaboration and licensing revenues plus partnership royalties. Total revenues in the reported quarter were approximately $1.6 million compared with $1 million registered in first-quarter 2018. However, revenues missed the Zacks Consensus Estimate of $2 million.. Shares of AVEO have plu...
Yahoo FinanceMay 1
AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019. The conference is being held May 7-8 in New York. About AVEO AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company is working to develop and commercialize its lead ca...
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
AVEO Pharmaceuticals, Inc. AVEO will report first-quarter 2019 earnings results. The company's performance over the last four quarters has been mixed so far with two earnings beat as well as a couple of misses. The average negative surprise over the trailing four quarters is 24.41%. In the las t report ed quarter, AVEO delivered a positive surprise of 50.00%. Shares of AVEO have plunged 40.5% so far this year against the industry's increase of 4.8%. Let's see, how things are shaping up for this announcem...
Expected Aug 6, Pre-Market